Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Study to obtain information about the co-operation of the different physician-colleagues in the treatment of patients with Parkinson's disease, both in private practices and clinics and about the primary treatment strategies in the pharmacotherapy of Parkinson's disease and to collect data on the tolerability of Sifrol® in ambulatory patients suffering from Parkinson's disease under routing conditions

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinsonian Disorders Synucleinopathies

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with Parkinson's disease who present to the specialist neurologist practice for the first time without or with referral and who are planned to receive or either be switched to Sifrol or continue the previously prescribed therapy with Sifrol® can be included in this observational study

Exclusion criteria

Neurologists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®

Treatment and study plan

Pramipexole

Drug

Other names: Sifrol®

Primary outcomes

Global Assessment of efficacy by investigator on a 4-point scale

Time frame: after 8 weeks
Change from Baseline in actual Parkinson symptoms

Time frame: Baseline, after 8 weeks
Global Assessment of tolerability by investigator on a 4-point scale

Time frame: after 8 weeks

Secondary outcomes

Number of patients with adverse drug reactions

Time frame: up to 8 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice

Important dates

Study start: 2003
Primary completion: 2003
First posted: Sep 25, 2014
Registry last updated: Sep 25, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed